We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Tenaya Therapeutics Inc | NASDAQ:TNYA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.07 | -1.65% | 4.18 | 3.99 | 4.16 | 4.285 | 3.81 | 4.25 | 1,007,150 | 00:31:26 |
“The successful execution across all of our program milestones slated for 2023, including two gene therapy INDs cleared and the dosing of the first patient in our TN-201 clinical trial, represents the strong commitment and capabilities of our team,” said Faraz Ali, Chief Executive Officer of Tenaya. “We have momentum as we head into 2024, with three clinical-stage programs for the treatment of rare and prevalent heart conditions and unmatched capabilities focused on the discovery of precision heart disease medications.”
Business and Program UpdatesTN-201 – Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy (HCM)
TN-401 – Gene Therapy for PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
TN-301 – Small Molecule HDAC6 Inhibitor for Heart Failure with Preserved Ejection Fraction (HFpEF)
Research
Third Quarter 2023 Financial Highlights
About Tenaya TherapeuticsTenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Leveraging its integrated and interrelated Gene Therapy, Cellular Regeneration and Precision Medicine platforms and proprietary core capabilities, the company is advancing a pipeline of novel therapies with diverse treatment modalities for rare genetic cardiovascular disorders and more prevalent heart conditions. Tenaya’s most advanced candidates include TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM), TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), and TN-301, a small molecule HDAC6 inhibitor being initially developed for heart failure with preserved ejection fraction (HFpEF). Tenaya also has multiple early-stage programs progressing through preclinical development. For more information, visit www.tenayatherapeutics.com.
Forward Looking StatementsThis press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Words such as “potential,” “anticipates,” “plans,” “expects,” and similar expressions are intended to identify forward-looking statements. Such forward-looking statements include, among other things, the clinical, therapeutic and commercial potential of, and expectations regarding, Tenaya’s product candidates; Tenaya’s plans and expectations regarding its clinical development efforts and activities, including the planned timing of sharing initial data from the Phase 1b clinical trial of TN-201 and planned initiation of a Phase 1b clinical trial of TN-401; the sufficiency of Tenaya’s cash resources to fund the company into the first half 2025; and statements made by Tenaya’s chief executive officer. The forward-looking statements contained herein are based upon Tenaya’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including but not limited to: risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and operating as an early stage company; Tenaya’s ability to develop, initiate or complete preclinical studies and clinical trials, and obtain approvals, for any of its product candidates; Tenaya’s continuing compliance with applicable legal and regulatory requirements; the availability of data at the referenced times; the potential for any clinical trial results to differ from preclinical, interim, preliminary, topline or expected results; Tenaya’s ability to raise any additional funding it will need to continue to pursue its business and product development plans; Tenaya’s reliance on third parties; Tenaya’s manufacturing, commercialization and marketing capabilities and strategy; the loss of key scientific or management personnel; competition in the industry in which Tenaya operates; Tenaya’s ability to obtain and maintain intellectual property protection for its product candidates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in documents that Tenaya files from time to time with the Securities and Exchange Commission. These forward-looking statements are made as of the date of this press release, and Tenaya assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
ContactMichelle CorralVP, Corporate Communications and Investor RelationsIR@tenayathera.com
InvestorsJulie SeidelStern Investor RelationsJulie.seidel@SternIR.com
MediaWendy RyanTen Bridge Communicationswendy@tenbridgecommunications.com
TENAYA THERAPEUTICS, INC.
Condensed Statements of Operations (In thousands, except share and per share data) (Unaudited)
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
2023 | 2022 | 2023 | 2022 | |||||||||||||
Operating expenses: | ||||||||||||||||
Research and development | $ | 23,091 | $ | 23,758 | $ | 75,173 | $ | 68,789 | ||||||||
General and administrative | 7,829 | 7,540 | 24,574 | 22,282 | ||||||||||||
Total operating expenses | 30,920 | 31,298 | 99,747 | 91,071 | ||||||||||||
Loss from operations | (30,920 | ) | (31,298 | ) | (99,747 | ) | (91,071 | ) | ||||||||
Other income, net: | ||||||||||||||||
Interest income | 1,776 | 596 | 5,586 | 917 | ||||||||||||
Other income, net | 1 | 6 | 12 | 5 | ||||||||||||
Total other income, net | 1,777 | 602 | 5,598 | 922 | ||||||||||||
Net loss before income tax expense | (29,143 | ) | (30,696 | ) | (94,149 | ) | (90,149 | ) | ||||||||
Income tax expense | — | — | — | — | ||||||||||||
Net loss | $ | (29,143 | ) | $ | (30,696 | ) | $ | (94,149 | ) | $ | (90,149 | ) | ||||
Net loss per share, basic and diluted | $ | (0.39 | ) | $ | (0.74 | ) | $ | (1.28 | ) | $ | (2.18 | ) | ||||
Weighted-average shares used in computing net loss per share, basic and diluted | 73,924,937 | 41,358,296 | 73,579,200 | 41,309,812 |
Condensed Balance Sheet Data (In thousands)(Unaudited)
September 30, | December 31, | |||||||
2023 | 2022 | |||||||
Cash, cash equivalents and marketable securities | $ | 128,120 | $ | 204,230 | ||||
Total assets | $ | 193,397 | $ | 278,945 | ||||
Total liabilities | $ | 28,513 | $ | 35,569 | ||||
Total liabilities and stockholders’ equity | $ | 193,397 | $ | 278,945 |
1 Year Tenaya Therapeutics Chart |
1 Month Tenaya Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions